369 related articles for article (PubMed ID: 32331305)
21. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
22. Advances in inflammatory bowel diseases in children.
Michail S; Ramsy M; Soliman E
Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review].
Volz MS; Siegmund B; Häuser W
Schmerz; 2016 Feb; 30(1):37-46. PubMed ID: 26809974
[TBL] [Abstract][Full Text] [Related]
24. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial.
Naftali T; Bar-Lev Schleider L; Almog S; Meiri D; Konikoff FM
J Crohns Colitis; 2021 Nov; 15(11):1799-1806. PubMed ID: 33858011
[TBL] [Abstract][Full Text] [Related]
25. The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats.
Szandruk M; Merwid-Ląd A; Szeląg A
Inflammopharmacology; 2018 Apr; 26(2):571-581. PubMed ID: 28337639
[TBL] [Abstract][Full Text] [Related]
26. Attitudes towards and use of cannabis in New Zealand patients with inflammatory bowel disease: an exploratory study.
Appleton K; Whittaker E; Cohen Z; Rhodes HM; Dunn C; Murphy S; Gaastra M; Galletly A; Dougherty S; Haren A; Sukumaran N; Aluzaite K; Dockerty JD; Turner RM; Schultz M
N Z Med J; 2021 Feb; 134(1530):38-47. PubMed ID: 33651776
[TBL] [Abstract][Full Text] [Related]
27. Cannabis finds its way into treatment of Crohn's disease.
Schicho R; Storr M
Pharmacology; 2014; 93(1-2):1-3. PubMed ID: 24356243
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory bowel disease: new therapies from antisense oligonucleotides.
Marafini I; Monteleone G
Ann Med; 2018 Aug; 50(5):361-370. PubMed ID: 29911450
[TBL] [Abstract][Full Text] [Related]
30. Roles of protein ubiquitination in inflammatory bowel disease.
Xiao Y; Huang Q; Wu Z; Chen W
Immunobiology; 2020 Nov; 225(6):152026. PubMed ID: 33190004
[TBL] [Abstract][Full Text] [Related]
31. A review of current evidence allied to step-up and top-down medication therapy in inflammatory bowel disease.
Salahudeen MS
Drugs Today (Barc); 2019 Jun; 55(6):385-405. PubMed ID: 31250843
[TBL] [Abstract][Full Text] [Related]
32. Current scenario in inflammatory bowel disease: drug development prospects.
Chandel S; Prakash A; Medhi B
Pharmacol Rep; 2015 Apr; 67(2):224-9. PubMed ID: 25712643
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
34. Medical marijuana for inflammatory bowel disease: the highs and lows.
Wynne J; Kozuch P
Scand J Gastroenterol; 2022 Feb; 57(2):197-205. PubMed ID: 34919496
[TBL] [Abstract][Full Text] [Related]
35. Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease.
Sreedhar R; Arumugam S; Thandavarayan RA; Karuppagounder V; Watanabe K
Drug Discov Today; 2016 May; 21(5):843-9. PubMed ID: 26995272
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases.
Retnakumar SV; Muller S
Trends Mol Med; 2019 Jun; 25(6):516-537. PubMed ID: 30952481
[TBL] [Abstract][Full Text] [Related]
37. [The use of methotrexate in an inflammatory bowel diseases based on the review of the current literature].
Klimczak K; Łykowska-Szuber L; Krela-Kaźmierczak I; Eder P; Szymczak A; Stawczyk-Eder K; Linke K
Wiad Lek; 2016; 69(2 Pt 2):262-6. PubMed ID: 27487545
[TBL] [Abstract][Full Text] [Related]
38. Current pharmacotherapy for inflammatory bowel disease.
McKaig BC; Stack WA
Expert Opin Pharmacother; 1999 Nov; 1(1):3-14. PubMed ID: 11249561
[TBL] [Abstract][Full Text] [Related]
39. Curcuminoids from
Cunha Neto F; Marton LT; de Marqui SV; Lima TA; Barbalho SM
Crit Rev Food Sci Nutr; 2019; 59(13):2136-2143. PubMed ID: 29565637
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoid resistance in inflammatory bowel disease.
Farrell RJ; Kelleher D
J Endocrinol; 2003 Sep; 178(3):339-46. PubMed ID: 12967327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
